Header Logo

Connection

Robin Jones to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications Robin Jones has written about Antineoplastic Agents.
Robin Jones
Connection Strength
6.814
Antineoplastic Agents
  1. KIT Exon 9-Mutated Gastrointestinal Stromal Tumours: Biology and Treatment. Chemotherapy. 2022; 67(2):81-90.
    View in: PubMed
    Score: 0.643
  2. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer. 2021 03; 145:132-142.
    View in: PubMed
    Score: 0.602
  3. Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. Eur J Cancer. 2019 10; 120:132-139.
    View in: PubMed
    Score: 0.548
  4. Olaratumab in soft tissue sarcoma - Current status and future perspectives. Eur J Cancer. 2018 03; 92:33-39.
    View in: PubMed
    Score: 0.490
  5. Drug repositioning in sarcomas and other rare tumors. EBioMedicine. 2016 Apr; 6:4-5.
    View in: PubMed
    Score: 0.430
  6. Current and advancing systemic treatment options for soft tissue sarcomas. Expert Opin Pharmacother. 2015; 16(13):2023-37.
    View in: PubMed
    Score: 0.396
  7. Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors. Clin Cancer Res. 2015 Feb 15; 21(4):693-700.
    View in: PubMed
    Score: 0.387
  8. A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors. Invest New Drugs. 2014 Feb; 32(1):171-7.
    View in: PubMed
    Score: 0.365
  9. New drugs and clinical trial design in advanced sarcoma: have we made any progress? Future Oncol. 2013 Oct; 9(10):1409-11.
    View in: PubMed
    Score: 0.358
  10. Clinical benefit of early phase clinical trial participation for advanced sarcoma patients. Cancer Chemother Pharmacol. 2011 Aug; 68(2):423-9.
    View in: PubMed
    Score: 0.297
  11. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther. 2006 Sep; 6(9):1249-69.
    View in: PubMed
    Score: 0.222
  12. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005 Dec; 41(18):2853-60.
    View in: PubMed
    Score: 0.210
  13. The development and application of imatinib. Expert Opin Drug Saf. 2005 Mar; 4(2):183-91.
    View in: PubMed
    Score: 0.200
  14. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. Clin Cancer Res. 2022 04 14; 28(8):1672-1679.
    View in: PubMed
    Score: 0.164
  15. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. J Clin Oncol. 2021 10 01; 39(28):3128-3139.
    View in: PubMed
    Score: 0.156
  16. Pharmacotherapy for liposarcoma: current and emerging synthetic treatments. Future Oncol. 2021 Jul; 17(20):2659-2670.
    View in: PubMed
    Score: 0.153
  17. Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. Eur J Surg Oncol. 2021 08; 47(8):2173-2181.
    View in: PubMed
    Score: 0.153
  18. Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. Oncologist. 2021 04; 26(4):e639-e649.
    View in: PubMed
    Score: 0.151
  19. Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. Med Oncol. 2018 Sep 05; 35(11):138.
    View in: PubMed
    Score: 0.128
  20. Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. Med Oncol. 2018 Aug 20; 35(10):131.
    View in: PubMed
    Score: 0.127
  21. Eribulin in advanced liposarcoma and leiomyosarcoma. Expert Rev Anticancer Ther. 2017 08; 17(8):717-723.
    View in: PubMed
    Score: 0.118
  22. The Current Landscape of Early Drug Development for Patients With Sarcoma. Am Soc Clin Oncol Educ Book. 2017; 37:807-810.
    View in: PubMed
    Score: 0.114
  23. Dear John Hunter. BMJ. 2016 12 14; 355:i6515.
    View in: PubMed
    Score: 0.113
  24. Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors. Future Oncol. 2017 Jan; 13(2):185-194.
    View in: PubMed
    Score: 0.111
  25. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep. 2014 Feb 13; 6(3):514-27.
    View in: PubMed
    Score: 0.093
  26. Gastrointestinal leiomyosarcoma demonstrate a predilection for distant recurrence and poor response to systemic treatments. Eur J Surg Oncol. 2021 10; 47(10):2595-2601.
    View in: PubMed
    Score: 0.038
  27. Beyond triple-negative breast cancer: the need to define new subtypes. Expert Rev Anticancer Ther. 2010 Aug; 10(8):1197-213.
    View in: PubMed
    Score: 0.018
  28. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat. 2008 Sep; 111(1):27-44.
    View in: PubMed
    Score: 0.015
  29. MYC amplification in breast cancer: a chromogenic in situ hybridisation study. J Clin Pathol. 2007 Sep; 60(9):1017-23.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.